Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1827 Target Snapshot

cGMP-specific 3',5'-cyclic phosphodiesterase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,669Compounds
432Assays
20Approved Drugs
4,559.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

cGMP-specific 3',5'-cyclic phosphodiesterase shows approved-linked disease relevance led by erectile dysfunction. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O76074. Start with erectile dysfunction, then reuse UniProt O76074 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with erectile dysfunction, then reuse UniProt O76074 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 5 linked drugs
Open source guide
Disease program
erectile dysfunction

cGMP-specific 3',5'-cyclic phosphodiesterase shows approved-linked disease relevance led by erectile dysfunction. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with erectile dysfunction because it currently carries approved-linked support. Linked drugs include AVANAFIL, SILDENAFIL CITRATE, TADALAFIL, UDENAFIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cGMP-specific 3',5'-cyclic phosphodiesterase as ChEMBL target CHEMBL1827, mapped to UniProt O76074. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
cGMP-specific 3',5'-cyclic phosphodiesterase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1827
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O76074
cGMP-specific 3',5'-cyclic phosphodiesterase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether cGMP-specific 3',5'-cyclic phosphodiesterase is the right protein anchor across sources, using UniProt O76074 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why erectile dysfunction is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamecGMP-specific 3',5'-cyclic phosphodiesterase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO76074
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelcGMP-specific 3',5'-cyclic phosphodiesterase
UniProt AccessionO76074
Component TypeProtein
Sequence Length875 aa

cGMP-specific 3',5'-cyclic phosphodiesterase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as cGMP-specific 3',5'-cyclic phosphodiesterase, mapped to UniProt O76074. Sequence length is 875 aa.

Mapped IDO76074
Review namecGMP-specific 3',5'-cyclic phosphodiesterase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

cGMP-specific 3',5'-cyclic phosphodiesterase shows approved-linked disease relevance led by erectile dysfunction. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
erectile dysfunction
5 linked drugs · 5 direct · 5 efficacy
Linked drugAVANAFIL
Linked drugSILDENAFIL CITRATE
Linked drugTADALAFIL
Linked drugUDENAFIL
Approved-linked Approved
Impotence
5 linked drugs · 5 direct · 5 efficacy
Linked drugAVANAFIL
Linked drugGISADENAFIL
Linked drugSILDENAFIL CITRATE
Linked drugTADALAFIL
Approved-linked Approved
pulmonary arterial hypertension
4 linked drugs · 4 direct · 4 efficacy
Linked drugPF-00489791
Linked drugSILDENAFIL CITRATE
Linked drugTADALAFIL
Linked drugUDENAFIL
Approved-linked Approved
benign prostatic hyperplasia
2 linked drugs · 2 direct · 2 efficacy
Linked drugGISADENAFIL
Linked drugTADALAFIL
Approved-linked Approved
pulmonary arterial hypertension
2 linked drugs · 2 direct · 2 efficacy
Linked drugSILDENAFIL CITRATE
Linked drugTADALAFIL
Approved-linked Approved
pulmonary hypertension
2 linked drugs · 2 direct · 2 efficacy
Linked drugSILDENAFIL CITRATE
Linked drugTADALAFIL
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with erectile dysfunction because it currently carries approved-linked support. Linked drugs include AVANAFIL, SILDENAFIL CITRATE, TADALAFIL, UDENAFIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseerectile dysfunction
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

20
Approved
4
Phase III
13
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC503,538.0
KI982.0
EC5030.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1916488 11.0 IC50 0.01 Preclinical
CHEMBL1916483 11.0 IC50 0.01 Preclinical
CHEMBL1098465 10.96 IC50 0.011 Preclinical
CHEMBL1916486 10.7 IC50 0.02 Preclinical
CHEMBL1916485 10.7 IC50 0.02 Preclinical
CHEMBL1916475 10.7 IC50 0.02 Preclinical
CHEMBL4759667 10.6 IC50 0.025 Preclinical
CHEMBL3654363 10.55 IC50 0.028 Preclinical
CHEMBL1520 10.54 IC50 0.029 Approved
CHEMBL410215 10.52 IC50 0.03 Preclinical
Distribution

pChEMBL Value Distribution

240
5.0
221
5.5
235
6.0
213
6.5
275
7.0
240
7.5
308
8.0
313
8.5
187
9.0
84
9.5
pChEMBL
Approved Drugs

Approved Drugs

AVANAFIL
CHEMBL1963681
Approved 2011
Properties Compare Identifier
VARDENAFIL
CHEMBL1520
Approved 2003
Properties Compare Identifier
VARDENAFIL HYDROCHLORIDE
CHEMBL1339
Approved 2003
Properties Compare Identifier
TADALAFIL
CHEMBL779
Approved 2002
Properties Compare Identifier
SILDENAFIL
CHEMBL192
Approved 1998
Properties Compare Identifier
SILDENAFIL CITRATE
CHEMBL1737
Approved 1998
Properties Compare Identifier
DONEPEZIL
CHEMBL502
Approved 1996
Properties Compare Identifier
MILRINONE
CHEMBL189
Approved 1987
Properties Compare Identifier
DIPYRIDAMOLE
CHEMBL932
Approved 1961
Properties Compare Identifier
Assay Landscape

Assay Landscape

432
Total Assays
2,257
Tested Compounds
3
Assay Types
Binding — 417 assays, 2,257 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 283 1,600 7.2
assay format 77 401 7.6
cell-based format 51 232 7.3
tissue-based format 6 24 6.4
ADME — 8 assays, 4 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 7 4 5.1
cell-based format 1 0 —
Functional — 7 assays, 9 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 5 2 9.5
tissue-based format 2 7 7.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine